Reaction profile

The FDA adverse-event record for pr-parathyroid, lesion(s)

Name: PR-PARATHYROID, LESION(S) - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

18 FDA reports name pr-parathyroid, lesion(s), a lower-volume reaction in the CVM extract (VeDDRA 99659). Plate stamps and neighbourhood peers follow.

#2226 of 2,481
by report volume (all reactions): 18
reports citing this reaction: 88.9%
death-coded share: Cat
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. PR-PARATHYROID, LESION(S) has 18 reports now versus 17 in that prior snapshot: 1 more (5.9%).

Report change: +1
Death-coded reports: +1
Death-coded share: +0.7 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to PR-PARATHYROID, LESION(S) changes

FDA AER · VeDDRA plate

Code 99659 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-CAT · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 18 reports
DEATH-HOT 88.9%
LOWER-Q #2226/2481
PHOTO-FINISH ALBUMIN/GLOBULIN RATI…
SPECIES-CAT Cat · 12
DRUG-LEAD Robenacoxib · 11
DESK-WIDE 10 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: ALBUMIN/GLOBULIN RATIO HI, BLD (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around PR-PARATHYROID, LESION

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around PR-PARATHYROID, LESION(S)

PR-PARATHYROID, LESION(S): high death-coded share in the FDA AER plate

Signature read: PR-PARATHYROID, LESION(S)'s 88.9% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 18 named reports in the openFDA extract. Death-coded share is upper-third: 16 of 18 reports (88.9% of named reports). Nearest volume peer: ALBUMIN/GLOBULIN RATIO HI, BLD (±0 reports). Lead species Cat (12). Lead co-reported drug Robenacoxib (11).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Cat 12

Dog 6

Breeds Most Affected

Domestic (unspecified) 9

Shepherd Dog - German 1

Crossbred Canine/dog 1

Cat (unknown) 1

Terrier - Bull - American Pit 1

Dachshund - Standard Long-haired 1

Domestic Shorthair 1

Terrier - Boston 1

Domestic Longhair 1

Dachshund (unspecified) 1

Associated Drugs

Robenacoxib 11

Buprenorphine 4

Cyclosporine 1

Deracoxib 1

Cefovecin 1

Food 1

Oclacitinib Maleate 1

Cefpodoxime Proxetil 1

Prednisone 1

Antibiotic 1

Milbemycin Oxime + Spinosad 1

Vitamin B12 1

Steroid (Unknown) 1

Chondroitin Sulfate 1

Medetomidine 1

Hydromorphone 1

Sevoflurane 1

Moxidectin 1

Unspecified Cushings Medication 1

Gabapentin 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for PR-PARATHYROID, LESION(S) (#2226 of 2,481 by report volume); death-coded 88.9%. PlainBreed reaction plate · death-coded share stamp 88.9% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →